Transcriptional profiling of human myxoid liposarcoma xenografts treated with trabectedin

ABSTRACT: To elucidate the mechanisms behind the high sensitivity of myxoid/round cell liposarcoma (MRCL) to trabectedin and the suggested selectivity for specific subtypes we have developed and characterized two MRCL xenografts differing for the breakpoint of the fusion gene FUS- HOP, respectively of type II and III. Transcription profiling experiments were carried out after trabectidin treatment in four separate time points (control, 24h after the first dose, 24h after the third dose, and 15 days after the third dose) for both types of xenografts in order to identify genes and pathways involved with the mechanisms of action of trabectedin in MRCL.

ORGANISM(S): Homo sapiens

SUBMITTER: Luca Beltrame 

PROVIDER: E-MTAB-1809 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress